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There have been several recent reports of non-convulsive status epilepticus during tiagabine therapy in patients with partial
epilepsy. We report three cases where elevation of tiagabine dosage was followed by electroclinical features, or electroen-
cephalographic features without clinical signs, of non-convulsive status epilepticus. Administration of clonazepam and/or
discontinuation to tiagabine lead to complete remission. In one case after re-exhibition of tiagabine the EEG again showed
rhythmic delta waves. We review the other cases reported so far and discuss the different pathophysiological hypotheses about
the association in the light of new experimental data.
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INTRODUCTION
Tiagabine (TGB), a nipecotic acid analogue, is a
relatively new anticonvulsant agent. It is a potent and
selective inhibitor of the reuptake of GABA from the
synaptic cleft into neurons and glial cells and therefore
increases the synaptic concentration of GABA1, 2.
It is metabolized in the liver, predominantly by a
cytochrome P450 enzyme1. TGB has been approved
for the adjunctive treatment of partial seizures
in the European Union, the USA, Australia and
New Zealand3.
It seems to be a relatively safe drug, adverse
events being mostly mild or moderate, related to
the typical side effects of anticonvulsants (dizziness,
headache, somnolence, ataxia)1, 3, 31. Like some other
anticonvulsants with a good effect on partial seizures,
it was found to increase the frequency and duration of
generalized spike-wave discharges in animal models.
However, there have been several recent reports
of tiagabine-associated non-convulsive status epilep-
ticus (NCSE) in patients not only with generalized
epilepsies4, 5, but also with partial epilepsies4, 6–11, 33.
Paradoxical effects of anticonvulsants are not un-
known, but seem to be sporadic and often associated
with intoxication12, 13. In the case of tiagabine, the
events occurred within the range of therapeutic doses
and serum concentrations. In this report we describe
another three patients with partial epilepsy and NCSE
during treatment with tiagabine, compare the cases
with the other cases reported so far, and discuss
the different hypotheses about possible underlying
pathomechanisms.
Case 1
In 1991 a 29-year-old patient suffered for the first
time from complex partial seizures (CPS), starting
with a feeling of dyspnoea and leading to reduction of
alertness, often followed by loss of consciousness and
amnesia. Manual automatisms and blank staring were
usually noticed. The seizures typically lasted some
minutes and appeared in clusters of four to six seizures
every 4–6 weeks.
Cranial MRI showed the residue of a small bleed
from a cavernoma in the left thalamus but no cortical
lesion. Neurologic examination was completely nor-
mal. The EEG repeatedly showed slow activity with
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Fig. 1: EEG-findings of our patient. (a) EEG performed while patient received 30 mg tiagabine and showed clinical signs of
non-convulsive status epilepticus, (b) EEG after administration of clonazepam and discontinuation of tiagabine, (c) EEG after
re-exhibition to 30 mg tiagabine under protection of clonazepam.
rare sharp waves in the left as well as the right fronto-
temporal regions, but never generalized epileptic
activity. Anticonvulsive therapy with phenytoin (max.
300 mg/day) did not reduce the frequency of seizures
significantly in spite of high serum concentrations
(>30 µg ml−1) and clinical signs of intoxication.
Because of the patient’s liver cirrhosis following
hepatitis C infection after blood transfusion during
the treatment of a monocytic leukaemia in 1980,
phenytoin was replaced by gabapentin in 1996. This
reduced seizure frequency to one or two seizures per
month, but did not control the seizures even with high
doses on the borders of tolerability. In 1997 therapy
was changed to carbamazepine monotherapy, but
seizure control could not be established either, even at
high dosage and serum concentration (1350 mg/day–
13.1 µg ml−1) and signs of intoxication (ataxia,
dizziness).
Therefore, adjunctive therapy with tiagabine was
started in 1998. Within 3 months the dosage was
increased step by step while carbamazepine was
reduced to avoid central nervous side effects. With a
combination of tiagabine (25 mg/day, serum concen-
tration 41 ng ml−1) and carbamazepine (600 mg/day,
serum concentration 6.7 µg ml−1), the seizure
frequency was further reduced, but in the summer of
1999, the patient still had one seizure every 3 months.
Therefore the tiagabine dose was increased to
30 mg/day (10 mg tid) in December 1999. Four
days after the increase the treating physician noticed
stereotypic oral and manual movements and a reduced
responsiveness from the patient. In a neurologic exam-
ination no focal deficits were found. One hour after the
symptoms had started, the EEG showed high voltage,
generalized, rhythmic delta activity (2–3/second) with
several sharp waves (Fig. 1(a)). Assuming tiagabine-
induced NCSE, the tiagabine administration was
stopped and clonazepam (3 mg i.v.) was given. The
patient recovered completely, and the EEG showed
pharmacologically induced precentral beta activity
and intermittent alpha-activity above the right fronto-
temporal region (Fig. 1(b)).
To support the suspicion of tiagabine-induced
NCSE, after obtaining informed consent from the
patient re-exhibition with 3 × 10 mg tiagabine
was started 3 days later (serum-concentration
120 ng ml−1) under the protection of a continuous
i.v.-administration of clonazepam (4 mg/day). The
patient remained alert and conscious; no seizures were
seen. However, the EEG again showed intermittent
rhythmic bilateral frontal theta-activity (Fig. 1(c)).
Therefore, tiagabine was discontinued. Three days
later, this EEG activity had significantly reduced.
Finally carbamazepine, which had been admin-
istered unchanged throughout these events, was
replaced by oxcarbazepine (900 mg/day). The patient
remained seizure free during a 5 month follow-up
period.
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Case 2
Since 1993 this 30-year-old female patient has
suffered from simple partial sensomotor seizures of
the left arm and leg. Apart from two tonic–clonic
seizures in 1993 no seizures with impairment of
consciousness had been reported. An EEG showed no
epileptic activity, but rare intermittent focal slowing
in both left and right temporal regions. A MRI
showed non-specific paraventricular parietal white
matter lesions but no cortical lesions were found.
Primidone and gabapentin, even in high doses,
did not control the seizures. Carbamazepine and
lamotrigine caused allergic skin rashes and had to
be discontinued. In 1998 therapy was changed to
valproate which initially reduced seizure frequency. A
few months later seizure frequency rose again despite
elevation of the valproate dose. A maximum dose of
1800 mg/day (96 ug ml−1) lead to intoxication. A
daily dose of 1650 mg valproate was tolerated well,
but seizure frequency remained unchanged (max. two
seizures/day).
In February 2000 topiramate was added (max.
350 mg/day, 12.73 ug ml−1), but frequency as well as
duration of the seizures further increased. In June 2000
topiramate was step by step replaced by tiagabine
while valproate was left unchanged. Misunderstanding
the prescription, the patient increased her tiagabine
dose to 25 mg/day within 2 weeks.
One week later, having been coincidentally admitted
to a neurological ward to diagnose the aetiology of
the white matter lesions, suddenly the patient was
found disoriented and confused. An EEG showed
generalized blunt delta waves of high amplitude and
sharp slow waves. After administration of 1 mg
clonazepam i.v. the rhythmic EEG patterns subsided.
The patient was tired but fully oriented. Tiagabine
was tapered completely within 2 weeks. Valproate
was elevated to 2000 mg/day without signs of
intoxication. The EEG showed a slight general
slowing, but no rhythmic patterns and no epileptiform
discharges. During a 5-month follow-up no similar
episode occurred.
Case 3
For 11 years the patient suffered from complex-partial
seizures with blurred vision and dyspnoea, followed
by loss of consciousness and movements of arms and
legs. The episodes were interpreted as cardiovascular
syncope until, in 1999, an EEG after sleep deprivation
showed a sharp-wave focus in the right temporal
region. Cranial MRI was completely normal.
Anticonvulsive therapy with lamotrigine was initi-
ated in September 1999, but had to be stopped due to
an idiosyncratic skin reaction (rash). With gabapentin
(max. 1200 mg/day) the patient became seizure-
free, but developed dose-dependent headache so that
gabapentin was tapered. In the following months
a few seizures occurred again. Because the patient
did not want to take an anticonvulsant which could
influence contraception tiagabine was added in steps
of 5 mg/week while tapering gabapentin completely.
The last seizure of the usual semiology was
experienced with tiagabine 15 mg/day, but the patient
reported short episodes where she had the feeling of a
slight alteration of consciousness and ‘slow thinking’.
These episodes occurred about four to five times dur-
ing May and June 2000 (tiagabine 20 and 25 mg/day)
and lasted from seconds up to 1 minute. At the
end of June during a routine examination (6 weeks
after reaching the maximum dose of 25 mg/day) an
EEG was conducted and showed frequent episodes
of generalized delta waves (2–3/second) and sharp
waves, lasting 10–15 seconds. During the whole exam-
ination no alteration of consciousness, concentration
nor psychomotor slowing was observed, neurologic
examination was completely normal, and the patient
did not report any unusual sensations.
Under coadministration of clobazam (15 mg/day)
tiagabine was reduced to 15 mg/day. Two weeks later
the patient remained seizure free and did not report
any episodes of alteration of consciousness. An EEG
showed some generalized theta and delta waves, and
again sharp waves over the right temporal region were
observed but no generalized rhythmic waves.
Tiagabine was tapered completely and substituted
by valproic acid. Four months later no seizures and
no episodes of alteration of consciousness had been
reported. An EEG remained unchanged without any
rhythmic waves.
DISCUSSION
Two of the patients suffered from an episode of
reduced responsiveness and manual/oral automatisms
after an increase of tiagabine dosage which could
be diagnosed by an ictal EEG as NCSE. The
diagnosis was confirmed by the immediate response
to clonazepam. Regarding the impaired liver function
of the patient, a sudden metabolic worsening is also
a potential reason for the NCSE in case 114. Routine
laboratory tests showed no significant decrease of
liver function, and the blood ammonia level was only
slightly elevated, not increased compared to previous
levels. The temporal correlation between the increase
in tiagabine dose and the occurrence of symptoms, the
positive re-exhibition (case 1) and the singularity of
the episode seem to corroborate the crucial role of
tiagabine in both cases.
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During the last 5 years, there have been reports of
16 cases of tiagabine associated NCSE in patients with
partial seizures (including these three cases). Table 1
shows important points of the reports.
All patients whose case reports contained sufficient
data suffered from partial epilepsy for at least 8 years.
Neither age nor sex seem to have influence on the
occurrence of NCSE. Aetiology of the epilepsy is
equally distributed among the patients. No patient had
generalized epileptic activity in his routine EEG. In all
cases but one, tiagabine was administered within the
therapeutic range of 25–50 mg daily.
In patients with hepatic dysfunction the elimination
of tiagabine is slowed and tiagabine serum concen-
tration increased15. In case 1, impaired liver-function
has probably altered the pharmacokinetics. But serum
concentrations before, during and shortly after the
event were within or near the lower limit of the
therapeutic range. Comedication consisted of agents
with a wide range of mechanisms of action. The
association of CPS and NCSE with a sudden rise
of carbamazepine-epoxide, as So and colleagues16
described, probably does not play an important role
for the majority of the reported cases. Comedication
was administered in a relatively high, but stable dosage
with the exception of a slight parallel increase (7,
case 2) or decrease (10, case 1; our case 2) in three
cases. An effect of comedication changes on tiagabine
concentration or vice versa seems improbable because
of the lack of a pharmacokinetic drug interaction
with tiagabine which is proven for carbamazepine,
phenytoin17 and valproate18.
In one of our patients (case 1) a confounding factor
can be found. All but one author could confirm the
clinical diagnosis of an NCSE (unresponsiveness, au-
tomatisms, staring) with generalized epileptic activity
in the EEG. EEG-activity was described relatively
uniformly as rhythmic, generalized slow activity,
typically 2–3/second, with additional sharp waves.
Intravenous administration of benzodiazepines, or,
in at least four cases, stopping tiagabine, terminated
the symptoms and, if an EEG was repeated, the
rhythmic activity as well. In two cases, tiagabine was
re-administered and worsened the EEG.
In a retrospective analysis of patients to whom
TGB was administered in clinical practice, we found
an incidence of 3/56 for NCSE. In contrast to that,
Shinnar et al.19 analysed 113 cases of NCSE which
occurred during tiagabine-therapy in 2468 patients.
They found no increased risk for NCSE compared
to that of other patients with intractable partial
seizures. However, NCSE may have gone undetected.
There were 13 patients where mental status change
associated with generalized spike-wave patterns was
reported during clinical trials and interpreted as
tiagabine-intolerance. They might have been experi-
encing NCSE6. In a recent publication Shinnar et al.
34 compared study safety data concerning NCSE with
data from cohorts of epidemiologic studies. They
found no increased incidence of status epilepticus nor
of NCSE in tiagabine-treated patients. Again, they
interpreted several NCSE-like episodes as ‘tiagabine-
intolerance’ without demonstrating operational crite-
ria for their decision.
In one of our patients (case 3), no EEG was done
during the spells, but an interictal EEG showed the
same reversible alterations as in the other patients. To
our knowledge no similar event during administration
of tiagabine has been reported so far. This could
be due to the non-specific and unspectacular nature
of these episodes with very short alterations in
consciousness which could have been missed in
routine examinations. In a retrospective analysis of
56 patients in our clinic to whom tiagabine was
administered as a clinical routine, at least three other
patients with similar episodes were found, but only in
two cases were these episodes considered as adverse
events of tiagabine30. Probably such patient reports
have been misinterpreted. Moreover, some patients
may have failed to report similar episodes. Therefore
the incidence of similar events may be underestimated.
There are different opinions about the underlying
pathological mechanisms. Trinka et al.9 suggested
that tiagabine at high doses might inhibit all neuronal
GABA-uptake and therefore lead to a depletion of
GABA in the presynaptic neuron, which is supposed
to underlie the generation of pharmacoresistant
late recurrent discharges in vitro20. Therefore, the
anticonvulsant effects of tiagabine would attenuate
with higher doses. Indeed, in animal experiments, such
an attenuating effect could be found21. The reason for
this effect remains unclear. The affinity of tiagabine
for neuronal reuptake transporters is markedly less
than its affinity for glial transporters22, and the
inhibition of glial GABA-transport plays a crucial role
in sustaining a high synaptic and presynaptic GABA
level23. Thus, synaptic tiagabine concentration must
be comparatively high to cause GABA-depletion.
Newer experimental data points to a slightly
different mechanism, although they do not disprove
the role of GABA-shortage in the presynaptic neuron
as a consequence of long-lasting blockage of reuptake.
In different animal models, tiagabine (and vigabatrin
as well) has proabsence effects. In the lethargic (lh/lh)
mouse model of absence seizures, tiagabine (and
vigabatrin) increased seizure frequency, as well as
duration, markedly24. In WAG/Rij-rats as a model of
non-convulsive absence epilepsy, tiagabine increased
both the number and mean duration of spike-
wave discharges. This effect was seen especially at
high dosage25. In an animal model of convulsive
status epilepticus, the administration of tiagabine
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could control the convulsive seizures but produced a
hyporeactive behavioural state with rhythmic spike-
wave patterns of high amplitude in the EEG. This
state and the EEG pattern could be reproduced even
in normal rats4. In hippocampal slices of Wistar rats,
tiagabine developed a proconvulsive effect at higher
concentrations20.
On a functional level, Richards et al.26 suggest that
absence seizures may arise from GABA-mediated tha-
lamic inhibition. Lancel et al.32 found that tiagabine
enhanced slow delta-activity during non-REM-sleep
of rats, whereas GABA-A-receptor agonists did
not have this effect. They assumed that GABA-B-
mediated, slow postsynaptic hyperpolarization could
enhance rhythmic oscillations of thalamic neurons
during sleep. A recent report of tiagabine-induced
frontal NCSE11 implies that similar effects could
arise from a GABA-effect on frontal and/or temporal
neuronal circuits.
On the receptor level, Chan and Young27 demon-
strated that inhibition of neuronal GABA-reuptake
and the following elevation of GABA-concentration
in the synaptic cleft activates presynaptic GABA-
B-receptors and thus shortens the GABA-A-receptor
mediated inhibitory postsynaptic potential by reducing
the synaptic release of GABA.
This could explain the immediate effect of ben-
zodiazepines on tiagabine-induced NCSE. Benzodi-
azepines have a significant effect only on GABA-A-
receptor mediated inhibition. In a situation where the
synaptic GABA-level is reduced by activated GABA-
B-receptors, benzodiazepines can enhance the effect
of the remaining GABA without further decreasing
the level by activating GABA-B-receptors. This point
of view is supported by the report of a baclofen
(also GABA-B-agonist)-induced NCSE28 and some
experimental data concerning the effect of baclofen on
rat models of absence seizures29.
The reason why NCSE occurs only in a relatively
few patients but within the therapeutic range of
the drug, remains unclear. On the basis of the
reported cases, no potential risk factors could be
identified. Furthermore, there is no explanation why
patients with partial seizures and no anamnestic or
encephalographic data for the presence of additional
idiopathic generalized epilepsy suffer from this effect
of tiagabine. Perhaps a hitherto unknown sensibility
for absence seizures respectively NCSE generating
structures to GABA-mediated inhibition is unmasked
by a sudden and unmeasurable rise of tiagabine serum
concentration. Moreover, an increased expression of
presynaptic GABA-B-receptors is a possible reason
for the unforeseen occurrence of NCSE in some
predisposed patients.
In spite of the good anticonvulsant effect and
relatively few side effects, the occurrence of NCSE
is a rare but underestimated adverse event during
tiagabine therapy. To elucidate possible risk factors
and underlying pathomechanisms, cases of NCSE
during tiagabine therapy should be reported. Episodes
of decreased responsiveness during therapy should be
monitored thoroughly by clinical examination as well
as EEG.
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